CNW/ – This week, The New England Journal of Medicine (NEJM) published results from Novo Nordisk’s phase 3 REDEFINE 1 trial ...

Novo Nordisk’s new weight-loss drug helped patients lose even more weight on average than its current Wegovy blockbuster ...

European Stoxx 600 index closed 0.28 per cent lower at 535.03, after touching its lowest level in over a month earlier in the ...

Novo Nordisk unveiled its latest data for a weight-loss drug candidate, but shares of the maker of Wegovy and Ozempic tumbled ...

On the Nasdaq, 2,389 stocks rose and 2,026 fell as advancing issues outnumbered decliners by a 1.18-to-1 ratio. The S&P 500 ...

Results from the Phase III REDEFINE 1 trial show that CagriSema led to a 22.7% mean weight reduction at 68 weeks in adults ...

Wall Street's main indexes opened subdued on Monday as investors awaited Iran's possible response to U.S. airstrikes on its ...

Novo Nordisk presented trial results from its trials evaluating the efficacy of CagriSema, another weight-loss drug. Patients ...

Novo Nordisk A/S scrapped a partnership with Hims & Hers Health Inc. after less than two months, saying the US company is ...

The report spotlights China’s rapid biopharma advancement, alongside a GLP-1 surge, caution surrounding M&A, and a rise in ...

Stocks rose Monday, with oil prices declining, following a restrained response by Iran to U.S. attacks over the weekend.